European Radiopharma & Nuclear Medicine 2026: Alpha Emitters, PET, Theranostics

Eckert & Ziegler (Berlin, Germany) operates as the European medical-isotope + nuclear-medicine + radiation-components anchor the directory surfaces. The company runs radiopharmaceutical components, radioisotope manufacturing, and nuclear-medicine supply at commercial scope, supplying radiation-therapy operators, PET/SPECT imaging programmes, and research institutions across Europe. Eckert & Ziegler is the directory’s default reference for sponsors needing bulk isotope supply, radiopharmaceutical components, or nuclear-medicine infrastructure partnership. Complementary supply comes from Chiron AS (Trondheim, Norway), which provides certified reference standards and isotope-labeled internal standards for analytical and regulatory workflows.

Oslo holds two alpha-emitter radiopharmaceutical operators the directory surfaces. Thor Medical ASA runs Radium-224 and Pb-212 (lead-212) production plus oncology radionuclide therapy programmes. Oncoinvent ASA runs a clinical-stage Radium-224-microsphere programme for ovarian peritoneal metastases. Together, the two operators form the Nordic alpha-emitter cluster. Alpha-emitters deliver highly localised radiation with short path length, attractive for oncology where spatially targeted cell kill is desirable; they have attracted clinical interest since Bayer’s Xofigo (Radium-223) commercialisation and across the wider Lutetium-177 + Actinium-225 therapeutic landscape. For sponsors running alpha-emitter programmes or partnerships, Oslo is where the directory concentrates European capacity.

Two directory operators cover peptide radiopharmaceuticals and theranostic antibodies. 3B Pharmaceuticals (Berlin, Germany) runs peptide radiopharmaceutical + oncology + companion-diagnostic programmes at clinical scope — peptide-targeted radioligand therapeutics where the peptide delivers the radioisotope to the tumor-associated receptor. Diaprost (Lund, Sweden) runs humanized antibody theranostics + prostate cancer radioimmunotherapy programmes + preclinical antibody licensing. Both operators sit at the discovery + clinical development layer rather than commercial-scale manufacturing; both typically partner with radioisotope suppliers like Eckert & Ziegler for the radiochemistry step.

PharmaSynth (Tartu, Estonia) runs PET and SPECT precursor synthesis, custom synthesis, and small-scale API production for radiopharmaceutical programmes. PET precursors are short-half-life compounds (often [18F]- or [11C]-labeled) that couple with on-site cyclotron radiochemistry to produce PET imaging agents. SPECT precursors are typically [99mTc]- or [123I]-based. PharmaSynth is the Baltic + Estonian entry point for research-grade PET/SPECT precursor synthesis at clinical-scale volumes.

Radiopharmaceuticals in the EU are governed by both EMA (Committee for Medicinal Products for Human Use) + national regulators (BfArM in Germany, Swissmedic in Switzerland, etc.) for therapeutic approval, AND by the relevant national radiation-protection agencies for radioisotope handling + facility licensing. EURATOM rules cover radiation safety. For PET and theranostic programmes, the short-half-life nature of many PET isotopes (F-18 at 110 min; C-11 at 20 min) means on-site cyclotron + radiochemistry lab infrastructure is often mandatory. Clinical-trial authorisation for radiopharmaceuticals goes through CTIS like any other IMP, with additional radiation-dosimetry and safety documentation. The EU Biotech Regulation 2026 brief covers the wider EMA + pharmaceutical-reform context.

Radiopharmaceutical logistics is a specialised sub-category of pharmaceutical cold chain. GDP-certified logistics operators (DHL Life Sciences & Healthcare, Kuehne+Nagel Healthcare, World Courier) all publish radiopharmaceutical handling capability, with time-critical distribution for short-half-life isotopes the defining constraint. Eckert & Ziegler operates its own radioisotope-specific distribution network for bulk supply. For long-half-life alpha-emitters (Radium-224 has a half-life of ~3.7 days), standard GDP logistics with radiation labeling is sufficient. For PET isotopes (F-18 half-life 110 min), cyclotron-adjacent infrastructure is the practical constraint — most programmes co-locate PET production with the clinical site. The European Pharma Cold Chain & GDP Logistics 2026 brief covers the non-radiopharma pharmaceutical distribution layer.

Match the decision to the programme. Medical-isotope or radioisotope supply: Eckert & Ziegler (Berlin). Peptide radiopharmaceutical partnership: 3B Pharmaceuticals (Berlin). Theranostic antibody or radioimmunotherapy (oncology, prostate cancer): Diaprost (Lund). Alpha-emitter (Radium-224, Pb-212) clinical programme partnership: Thor Medical (Oslo) or Oncoinvent (Oslo). PET/SPECT precursor custom synthesis: PharmaSynth (Tartu). Certified reference standards + isotope-labeled internal standards for analytical work: Chiron AS (Trondheim). The Nordic Biotech Landscape 2026 brief covers the wider Nordic + Oslo context around the alpha-emitter cluster.